Panther Fusion® SARS-CoV-2/Flu A/B/RSV Assay

A fully-automated approach to testing of SARS-CoV-2, respiratory syncytial virus (RSV), influenza A (Flu A) and influenza B (Flu B) in one single assay.1

Assay box in lab background




    Respiratory Testing & Patient-Specific Results

    SARS-CoV-2, Flu A, B and RSV are the respiratory viruses with the highest disease burden for the human population.1,2 Some symptoms of COVID-19, flu and RSV are similar, making diagnosis based on symptoms alone virtually impossible.1

    Increase Efficiency & Reduce Costs

    Accurate and timely diagnosis of the cause of respiratory tract infections has a number of benefits for patients and their communities.

    Reduces Complications

    Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.1,3

    Patient Care First

    Potential to improve patient care and helps decrease costs.1,3,4

    Results with Purpose

    Provides valued information to public health authorities regarding which viruses are circulating in the community.1,5

    Helps Minimise Spread

    Assists infection control personnel to provide appropriate measures to minimise nosocomial spread.1,6

    Simplify & Scale the Future of Diagnostics

    The Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient rapid result to population-level screening.

    Technician walking through Panther systems in a lab setting

    Be Prepared for the Winter Respiratory Season

    The Panther Fusion assay shows excellent clinical performance.1

    98.1% Sensitivity

    98.5% specificity SARS-CoV-2

    100% Sensitivity

    99.6% specificity Influenza A

    98.1% Sensitivity

    99.6% specificity Influenza B

    98.1% Sensitivity

    100% specificity RSV

    Challenges Facing Laboratories

    The COVID-19 pandemic put unprecedented pressures on laboratories across the globe.

    • Huge sample demand, underscoring the need for high-throughput molecular automation7
    • Requirement to deliver rapid results to patients and clinicians7
    • Uncertainty around the future for SARS-CoV-2 and other respiratory viruses8,9

    Hologic was in the right place at the right time to make a profound impact on human health. Learn more about our collaboration and journey with labs during the pandemic and beyond.

    Lab technician pressing buttons on monitor

    Verified Sample Collection

    Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is validated for nasopharyngeal swabs in viral transport medium and universal transport medium.1

    Evidence. Insight. Collaboration.

    Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

      1. Panther Fusion SARS-CoV-2/Flu A/B/RSV assay [package insert]. AW-25328-001 Rev. 001. San Diego, CA: Hologic, Inc.; 2022
      2. Troeger C. et al GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4. Epub 2018 Sep 19. PMID: 30243584; PMCID: PMC6202443.
      3. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing. J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893.
      4. Accessed August, 2022.
      5. WHO-2019-nCoV-Surveillance-Guidance-2022.1-eng.pdf Accessed October, 2022.
      6. Lim RHF, Htun HL, Li AL, Guo H, Kyaw WM, Hein AA, Ang B, Chow A. Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19. Int J Infect Dis. 2022 Apr;117:139-145. doi: 10.1016/j.ijid.2022.01.069. Epub 2022 Feb 4. PMID: 35124240; PMCID: PMC8813202.
      7. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021 Mar;19(3):171-183. doi: 10.1038/s41579-020-00461-z. Epub 2020 Oct 14. PMID: 33057203; PMCID: PMC7556561.
      8. Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. Lancet. 2022 Jul 14:S0140-6736(22)01277-6. doi: 10.1016/S0140-6736(22)01277-6. Epub ahead of print. Erratum in: Lancet. 2022 Jul 18;: PMID: 35843260; PMCID: PMC9282759.
      9. Baker RE, Park SW, Yang W, et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30547-30553. doi: 10.1073/pnas.2013182117. Epub 2020 Nov 9. PMID: 33168723; PMCID: PMC7720203.



      Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.

      Notified Body number wherever applicable

      EC Representative Information wherever applicable